Featuring an interview with Dr Priyanka Sharma, including the following topics:

• Patient-reported outcomes from the SERENA-6 trial of camizestrant with a CDK4/6 inhibitor for patients with HR-positive, HER2-negative advanced breast cancer and ESR1 mutations emerging during first-line endocrine-based therapy (0:00)
  • Mayer E et al. Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC). ESMO 2025;Abstract 486MO.
• Imlunestrant and abemaciclib versus fulvestrant and abemaciclib for ER-positive, HER2-negative advanced breast cancer: An indirect treatment comparison of 3 Phase III trials (3:00)
  • Bidard FC et al. Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): An indirect treatment comparison (ITC) of three phase 3 trials. ESMO 2025;Abstract 496P .
• Giredestrant in the treatment of ER-positive, HER2-negative breast cancer: The Phase III evERA Breast Cancer and EMPRESS trials (5:39)
  • Mayer E et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. ESMO 2025;Abstract LBA16.
  • Llombart-Cussac A et al. Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) and Ki67≥10% early breast cancer (EBC): The EMPRESS study. ESMO 2025;Abstract 294MO.
• Capivasertib/fulvestrant as first- and second-line endocrine-based therapy for PIK3CA/AKT1/PTEN-altered HR-positive advanced breast cancer in the CAPItello-291 trial and gedatolisib/fulvestrant with or without palbociclib for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer in the VIKTORIA-1 trial.(10:25)
  • Rugo HS et al. Capivasertib plus fulvestrant as first and second-line endocrine-based therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the phase 3 CAPItello-291 trial. ESMO 2025;Abstract 526P.
  • Hurvitz SA et al. Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1. ESMO 2025;Abstract LBA17.

CME information and select publications

Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics:

• Introduction: Oral Selective Estrogen Receptor Degraders (SERDs) for the General Medical Oncologist (0:00)
• SERD Monotherapy (13:34)
• SERD and CDK Inhibitor Combination — The EMBER-3 Study (35:58)
• SERDs for "Molecular Progression" — The SERENA-6 Study (41:25)

CME information and select publications

Featuring an interview with Dr Priyanka Sharma, including the following topics:

• T-DXd versus trastuzumab emtansine for high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of the DESTINY-Breast05 trial (0:00)
  • Geyer C et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. ESMO 2025;Abstract LBA1. 
• DESTINY-Breast11 trial: Neoadjuvant T-DXd alone or followed by paclitaxel/trastuzumab/pertuzumab for high-risk HER2-positive localized breast cancer (5:42)
  • Harbeck N et al. DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). ESMO 2025;Abstract 291O. 
• Trastuzumab deruxtecan (T-DXd) and pertuzumab versus a taxane, trastuzumab and pertuzumab for HER2-positive advanced or metastatic breast cancer: Additional analyses of the DESTINY-Breast09 trial (10:00)
  • Loibl S et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest. ESMO 2025;Abstract LBA18. 

CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Kristen K Ciombor, including the following topics:

• Introduction: Assessment of HER2 Status (0:00)
• Case: An otherwise healthy woman in her early 50s with HER2-positive metastatic gallbladder cancer and multiple intrahepatic metastases — Jeremy Lorber, MD (7:33)
• Case: A man in his late 60s with HER2-low metastatic gallbladder cancer — Brian P Mulherin, MD (11:58)
• Data Review: Biliary Tract Cancers (18:19)
• Case: A man in his mid 50s with HER2-positive metastatic rectal cancer — Sunil Gandhi, MD (26:25)
• Case: A woman in her early 60s with recurrent HER2-positive rectal cancer — Ranju Gupta, MD (31:31)
• Data Review: Colorectal Cancer (34:16)
• Case: An otherwise healthy man in his mid 50s with HER2-positive metastatic gastroesophageal junction cancer and several metastatic liver lesions — Shachar Peles, MD (38:06)
• Case: A man in his early 60s with recurrent HER2-positive, claudin 18.2-positive metastatic esophageal cancer — Susmitha Apuri, MD (43:21)
• Data Review: Gastroesophageal Cancer (46:55)
• Case: A man in his early 60s with HER2-positive esophageal cancer and isolated brain metastases — Priya Rudolph, MD, PhD (50:07)

CME information and select publications

Featuring an interview with Dr Erika Hamilton, including the following topics:

• General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00)
• Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11)
• Mechanisms of resistance to endocrine therapy (10:08)
• Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26)
• Other applications for PROTACs (24:24)
• Emerging data from the Phase III evERA trial (27:38)
• Perspectives on clinical investigator and general medical oncologist practice pattern survey results (30:51)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics:

• Mechanisms of endocrine resistance; incidence of ESR1 mutations in breast cancer (0:00)
• Testing methods for ESR1 mutations in patients with breast cancer; therapeutic options for patients with ESR1-mutant breast cancer (3:59)
• General overview of proteolysis-targeting chimeras (PROTACs); comparison of PROTAC estrogen receptor (ER) degraders and selective ER degraders (7:39)
• Early-phase data with vepdegestrant monotherapy or in combination with CDK4/6 inhibitors in ER-positive, HER2-negative metastatic breast cancer (mBC) (11:54)
• Phase III VERITAC-2 trial of vepdegestrant versus fulvestrant in ER-positive, HER2-negative mBC previously treated with endocrine therapy and a CDK4/6 inhibitor (17:48)
• Ongoing clinical trials evaluating vepdegestrant in novel combinations or treatment settings; other clinical applications of PROTACs (26:08)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson and Dr Manali Kamdar, including the following topics:

• Introduction: About This Program (0:00)
• Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (3:10)
• Potential Treatment Benefits of CAR T-Cell Therapy (10:35)
• CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) (34:32)
• Finding Information About CAR T; Clinical Trials (42:17)
• Financial Issues; Risk of Infection (48:11)
• Coping with Anxiety; Healing and Moving On (55:17)

Educational and presenter information

Featuring slide presentations and related discussion from Prof Francois-Clement Bidard, Dr Hope S Rugo, Dr Rebecca Shatsky and Dr Seth Wander, including the following topics:

• Optimal approach to biomarker testing for patients with ER-positive metastatic breast cancer (mBC) (0:00)
• Case: A woman in her early 70s with recurrent ER-positive, HER2-negative mBC receives elacestrant (15:15)
• Case: A woman in her early 60s with ER-positive, HER2-low, PIK3CA-mutated mBC receives inavolisib-based therapy and experiences no disease progression for 24 months (18:02)
• Role of oral selective estrogen receptor degrader (SERD) monotherapy in the treatment of progressive ER-positive, HER2-negative mBC (26:26)
• Case: A woman in her mid 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (44:12)
• Case: A woman in her early 50s with recurrent HR-positive, HER2-negative, PIK3CA-mutant mBC receives capivasertib and fulvestrant (45:33)
• Potential novel applications of oral SERDs in the management of ER-positive, HER2-negative breast cancer (51:25)
• Case: A woman in her mid 50s with recurrent ER-positive, HER2-negative, PIK3CA-mutated mBC experiences disease progression 18 months after starting first-line letrozole and ribociclib (1:03:46)
• Case: A woman in her mid 50s with ER-positive, HER2-negative breast cancer undergoes serial ctDNA monitoring during first-line therapy (1:06:54)
• Tolerability and other practical considerations with oral SERDs (1:14:30)
• Case: A woman in her early 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (1:33:26)
• Case: A woman in her early 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (1:37:38)

CME information and select publications